Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas - Report - MDSpire

Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas

  • By

  • Julia A. Yescas

  • Christopher G. Bunick

  • Ayman Grada

  • Joan Guitart

  • Carlos A. Torres-Cabala

  • I. Caroline Le Poole

  • Xiaolong A. Zhou

  • May 13, 2026

Share

Clinical Report: Resistance Mechanisms to Kinase Inhibitors in CTCL

Overview

This report highlights the resistance mechanisms to tyrosine kinase inhibitors (TKIs) in cutaneous T-cell lymphomas (CTCL), particularly in aggressive subtypes PCAETL and PCGDTL. It emphasizes the need for molecular stratification and combination strategies to overcome adaptive resistance.

Background

Cutaneous T-cell lymphomas (CTCLs) represent a diverse group of skin-homing T-cell malignancies with limited treatment options. Aggressive subtypes such as primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma (PCAETL) and primary cutaneous gamma/delta T-cell lymphoma (PCGDTL) are associated with poor survival rates. Understanding the molecular drivers and resistance mechanisms is crucial for developing effective targeted therapies.

Data Highlights

No numerical data available in the source material.

Key Findings

  • Genomic studies identified recurrent alterations in tyrosine kinase signaling pathways in PCAETL and PCGDTL.
  • TKIs like ruxolitinib and cerdulatinib show meaningful but often transient responses in aggressive CTCL subtypes.
  • Acquired resistance to TKIs is frequently due to secondary kinase domain mutations and adverse events necessitating dose reductions.
  • Structural modeling indicates steric interference and altered ATP affinity as mechanisms limiting TKI efficacy.
  • Molecular stratification and longitudinal genomic monitoring are essential for achieving durable responses in CTCL.

Clinical Implications

Clinicians should consider the potential for adaptive resistance when using TKIs in CTCL treatment. Ongoing genomic monitoring and combination therapies may enhance treatment efficacy and patient outcomes in aggressive CTCL subtypes.

Conclusion

The findings underscore the complexity of treating aggressive CTCLs with TKIs and highlight the importance of personalized approaches in overcoming resistance mechanisms.

References

  1. Blood Cancer Journal, 2022 -- Exploring Resistance Mechanisms in Targeted Treatments: Focus on FLT3 and IDH
  2. Blood Cancer Journal, 2025 -- CDK9 as a Critical Factor in GATA-3 Driven T-cell Lymphomas Independent of MCL-1
  3. Blood Cancer Journal, 2024 -- Exploiting KDM5 Inhibition for Treatment of Mantle Cell Lymphoma
  4. Blood Cancer Journal, 2023 -- Zanubrutinib: An Overview of Its Historical Development, Current Applications, and Future Prospects
  5. NCCN Guidelines for Primary Cutaneous Lymphomas
  6. Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/Janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma - PMC
  7. Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma - PMC

Original Source(s)

Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas

  • by Julia A. Yescas, Christopher G. Bunick, Ayman Grada, Joan Guitart, Carlos A. Torres-Cabala, I. Caroline Le Poole, Xiaolong A. Zhou

  • May 13, 2026

Related Content

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants

Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American...

Unique Phase I NSCLC Trial Sites Decreasing in United States

The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant conso...